Robert and Ellen Kapito Professor of Pediatrics; Chief, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation
Pediatric Hematology & Oncology
Dr. Andrew L. Kung, MD
|
|
Give Review
Andrew Kung works in the field of Pediatric Hematology & Oncology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine He has 1 awards "Elected Member". Doctor Andrew L. Kung, MD is also published. He has 101 publications published. The lastest publication: "Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation.'
Publications
- Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation.
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice.
- Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer.
- 18F-FDG-PET/CT Imaging of Drug-Induced Metabolic Changes in Genetically Engineered Mouse Lung Cancer Models.
- Quantitative bioluminescence imaging of mouse tumor models.
- Preclinical magnetic resonance imaging in mouse cancer models.
- Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis.
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
- The Efficacy of Tacrolimus/Mycophenolate Mofetil as Acute Graft-Versus-Host-Disease Prophylaxis and the Impact of Sub Therapeutic Tacrolimus Levels in Children Followi...
- Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
- Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
- Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo.
- NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis.
- Computational repositioning and preclinical validation of pentamidine for renal cell cancer.
- Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant ...
- An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
- D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
- Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance.
- Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.
- Using Glow Stick Chemistry for Biological Imaging.
- Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activ...
- Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer.
- Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
- A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells.
- AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
- Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation.
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
- Oncogenic BRAF Regulates Oxidative Metabolism via PGC1? and MITF.
- Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer.
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute ...
- Shikonin, a natural product from the root of Lithospermum erythrorhizon, is a cytotoxic DNA-binding agent.
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
- Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
- In Vivo imaging of inflammatory phagocytes.
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
- Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency.
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
- Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
- Molecular and cellular effects of NEDD8 activating enzyme (NAE) inhibition in myeloma.
- Mice heterozygous for CREB binding protein are hypersensitive to ?-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.
- P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
- Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.
- BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
- Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression...
- High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.
- A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo.
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L.
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor.
- A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
- Crebbp haploinsufficiency in mice alters the bone marrow microenvironment leading to loss of stem cells and excessive myelopoiesis.
- Differentiation of NUT midline carcinoma by epigenomic reprogramming.
- Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
- Inactivation of a Single Copy of Crebbp Selectively Alters Pre-mRNA Processing in Mouse Hematopoietic Stem Cells.
- Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
- Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.
- Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
- A stapled p53 helix overcomes HDMX-mediated suppression of p53.
- Discovery and characterization of novel mutant FLT3 kinase inhibitors.
- Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper...
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
- An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
- Systematic in vivo structure-function analysis of p300 in hematopoiesis.
- Proteomic and genetic approaches identify Syk as an AML target.
- CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.
- HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
- Identification of AML1-ETO modulators by chemical genomics.
- The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity.
- In vivo pharmacodynamic imaging of proteasome inhibition.
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
- Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
- Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
- Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis.
- HOXA9 is required for survival in human MLL-rearranged acute leukemias.
- Lipocalin 2 promotes breast cancer progression.
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
- H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
- Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.
- Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
- Anti-apoptosis mechanisms in malignant gliomas.
- Therapeutic targeting of apoptosis pathways in cancer.
- Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
- Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
- Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
- Practices and pitfalls of mouse cancer models in drug discovery.
- Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
- Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
- CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
- Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.
- A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy.
- Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.
- Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longi...
Schools
Stanford University School Of Medicine
Childrens Hospital Boston
Children39s Hospital Boston
Dana Farber Canc Institute Chldns Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Doctors Specialties
- Pediatrics
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Boston Children's Hospital -
Stanford University School of Medicine
Hospital
-
NewYork-Presbyterian/Columbia
Helpful Reviews
Similar Doctors
|
Dr. Colin Sieff, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alison Friedmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina K. Ullrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer C. Kesselheim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alejandro Gutierrez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Eileen Brigid O'Keefe, MB BCH |
|
|
Dr. Kirsten E. Limmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew R. Vogt, MD |
|
|
Dr. Cecil D. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin N. Fogel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maya S. Venkataramani, MD |
|
|
Dr. Samuel E. Lux IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel Hudgins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn S. Porter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa M. Vente, DO |
|
|
Dr. Amy E. Sobota, MD
This Doctor is OpenDoctor Recommended.
|